The therapeutic effect of oral insulin sensitizer metformin on lipid profile in women with polycystic ovary syndrome.
01 Mar 2023-Iss: 336, pp 59-62
TL;DR: In this paper , the effects of metformin on lipid profiles were evaluated in polycystic ovarian syndrome patients with hyperinsulinemia and showed a significant difference in total cholesterol, LDL-C, HDL-C and triglyceride.
Abstract: A patient with polycystic ovary syndrome suffered from hyperinsulinemia and consequently lipid profile problems. This study evaluated the effects of metformin on lipid profiles. In a case-control study, a total of one hundred women were included in the study, fifty women that don't take metformin as the control group and fifty women that took metformin as the case group, Blood Samples were taken to know the effect of metformin on total cholesterol, LDL-C, HDL-C, and triglyceride, the dose of metformin was (500-850 mg daily) taken for 3-6 month. The Result of this study shows a significant difference in TC (Mean Difference=0.38), TG (Mean Difference =0.18), LDL (Mean Difference =0.3), and a nonsignificant difference (Mean Difference=-0.027) in HDL value. The present study supports the idea that metformin improves lipid profiles, so metformin may be considered as prophylactic therapy lowering cardiovascular risks in women with polycystic ovary syndrome.